DJIA 18,024.06 183.54 1.03%
NASDAQ 5,005.39 63.97 1.29%
S&P 500 2,108.29 22.78 1.09%
market minute promo


2.31 0.08 (3.59%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $2.31 3.59%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.27
Previous Close $2.23
Daily Range $2.24 - $2.32
52-Week Range $2.22 - $5.95
Market Cap $240.0M
P/E Ratio -2.79
Dividend (Yield) $0.00 (0.0%)
Volume 1,506,377
Average Daily Volume 1,884,064
Current FY EPS -$1.30




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War

Building a better mousetrap.

Why Vivus Is Undervalued At Anything Under $10 Per Share

Vivus Inks Deal To Make Qsymia More Affordable, But Will It Spur Sales?

The 52-Week Low Club for Tuesday

Vivus-Qsymia Sales Continue To Stumble Along - Equity Does The Same

Orexigen: Contrave Sales Pop, Equity Response Muted

Orexigen Has Contrave Recapturing Early-Year Form, But Needs European Launch

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough

What Novo Nordisk's Entry Into The Obesity Space Means To The Sector

See More VVUS News...

VVUS's Top Competitors

VVUS $2.31 (3.59%)
Current stock: VVUS
JNJ $100.13 (0.94%)
Current stock: JNJ
NVS $103.35 (1.52%)
Current stock: NVS
RHHBY $36.04 (0.45%)
Current stock: RHHBY